Robert T. Manguso

This paper introduces a lenalidomide-inducible suicide switch for gene- and cell-based therapies that enables safe and effective cell depletion without detectable leakiness.

This study identifies Dusp5 and Zfp219 as key regulators of age-related T cell dysfunction using CRISPR screens and shows their potential as therapeutic targets.

The paper identifies Trim28 as a regulator of CD8 T cell differentiation in tumors using clonally-resolved CRISPR screens and shows its role in maintaining TCF7+ stem-like cells while impairing effector differentiation.

This study identifies a novel CD8+ TIL subset that uses lymphotoxin and IFN pathways to kill cancer cells, linking LTB expression to clinical response in melanoma.

The paper uses in vivo CRISPR screens to identify genes affecting CAR T cell persistence and function in multiple myeloma, finding CDKN1B as a key regulator of late-stage CAR T cell fitness.

This study shows that targeting CD38 improves T cell function and restores response to immunotherapy in melanoma models.

The paper identifies CD43 as a glyco-immune checkpoint that inhibits human macrophage phagocytosis, showing that O-linked glycosylation and sialylation pathways regulate this process in AML.

This study develops lentiviral vectors with improved specificity and reduced immune clearance for in vivo CAR T cell generation, showing efficacy in a preclinical model.

The paper identifies CREB5 as a driver of immunotherapy resistance in melanoma by promoting collagen matrix deposition, which activates LAIR1 signaling on immune cells.

This paper introduces Perturb-FISH, a method combining spatial transcriptomics and CRISPR screening to study transcriptional circuits, showing intracellular and intercellular effects in immune and neurological contexts.